miércoles, 22 de enero de 2025

Medicare announces plan to negotiate prices of diabetes, weight loss drugs 15 drugs for conditions like cancer included in second round of price talks

Medicare announces plan to negotiate prices of diabetes, weight loss drugs 15 drugs for conditions like cancer included in second round of price talks https://www.statnews.com/2025/01/17/medicare-drug-price-negotiation-list-includes-ozempic-wegovy-ibrance-trelegy-ellipta-xtandi/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-_oCfZr_ObXHLH1nrQpLf006j8AyjWI0RS3m-Qg0XrBfmtneXWdqMBheIYX7MI8JBgQAdUpApVfPoDFKievBhl1WcENyA&_hsmi=343359550&utm_content=343359550&utm_source=hs_email We knew this day was coming. The big news in drug pricing landed Friday, with diabetes and weight loss drugs Ozempic and Wegovy leading the list of 15 medications whose prices will be negotiated this year under the Inflation Reduction Act, a signature achievement for the Biden administration. That doesn’t mean it’s a done deal under the new president. Congress or Mehmet Oz, nominated to lead Medicare and Medicaid, could tinker with the program, which also includes drugs for cancer. STAT’s Rachel Cohrs Zhang has the story and Joe Grogan has his take in this First Opinion. Former Trump health official: Medicare should cover Wegovy — but not negotiate its price Price controls are a surefire way to crush innovation https://www.statnews.com/2025/01/17/former-trump-health-official-medicare-should-cover-wegovy-but-not-negotiate-its-price/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9jgUAChvWGhcGtqwJKWDvMv42Q6cPlBBuk3cIat38CqKWyrgxY3hGv5vJq1PmqnFL-2TERlStMd7XbMGVaoJ6QNcWBlA&_hsmi=343359550&utm_content=343359550&utm_source=hs_email

No hay comentarios:

Publicar un comentario